AI assistant
CorMedix Inc. — Director's Dealing 2015
Mar 3, 2015
32333_dirs_2015-03-03_0da335ee-0c3a-4852-9a1e-5da3d381a6a1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2015-03-02
Reporting Person: Duffy Matthew (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-03-02 | Stock Option (right to buy) | $5.62 | A | 50000 | Acquired | 2025-03-01 | Common Stock, $0.001 par value per share (50000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.001 par value per share | 38339 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.02 | 2024-01-09 | Common Stock, $0.001 par value per share (150000) | 150000 | Direct |
| Stock Option (right to buy) | $2.02 | 2024-01-09 | Common Stock, $0.001 par value per share (30000) | 30000 | Direct |
| Stock Option (right to buy) | $0.9 | 2023-03-20 | Common Stock, $0.001 par value per share (100000) | 100000 | Direct |
| Stock Option (right to buy) | $0.68 | 2022-12-05 | Common Stock, $0.001 par value per share (125000) | 125000 | Direct |
| Warrant (right to purchase Common Stock) | $0.4 | 2017-11-13 | Common Stock, $0.001 par value per share (25000) | 25000 | Direct |
| Stock Option (right to buy) | $0.29 | 2022-01-06 | Common Stock, $0.001 par value per share (30000) | 30000 | Direct |
| Stock Option (right to buy) | $0.28 | 2021-11-21 | Common Stock, $0.001 par value per share (30000) | 30000 | Direct |
| Warrant (right to purchase Common Stock) | $3.475 | 2015-03-24 | Common Stock, $0.001 par value per share (4884) | 4884 | Direct |
Footnotes
F1: These options vested 100% on January 10, 2014.
F2: These options vest in full on the first anniversary of the date of grant.
F3: These options vest quarterly over two years.
F4: These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
F5: On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
F6: The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
F7: The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.